Article
Cautious Optimism For Capital Markets
Life sciences capital markets in 2025 have been a mixed bag—some rays of light peeking through, but still, plenty of clouds for early-stage companies hoping to tap the public markets.

Ballard Spahr LLP
Use advanced search filters to refine your search

